Business News • PR NewsWire • FDA Grants Orphan Drug Designation to Bayer's Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors

FDA Grants Orphan Drug Designation to Bayer's Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors

FDA Grants Orphan Drug Designation to Bayer's Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors

WAYNE, N.J., Feb. 4, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administ

View More : http://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-to-bayers-investigational-compound-regorafeni...

Releted News by prnewswire

India's First Web TV 'Indiavibes' Launches & Silicon Valley Based Potmax LLC Signs a Deal that Enables Joint Production/Marketing of Indian and American Content Across Both Countries

CarWoo! Revolutionizes Online New Car Marketplace With Comprehensive Transaction Tools Including Lease Negotiation

First Study Estimates Economic Impact of Dengue Illness in Americas at $2.1 Billion Per Year